We are pioneering a method to discover and develop new small-molecule medicines that achieve ‘protein silencing’ to create highly effective therapies for a broad range of diseases. We are able to silence the activity of disease-causing proteins by selectively forming strong and durable covalent bonds. While there are approved covalent drugs that arose from serendipitous discovery, we are the first company to design and develop targeted covalent drugs robustly, systematically and across the vast majority of target classes. This is enabled by our proprietary Avilomics™ platform.
While 2012 saw some spectacularly large IPOs like Facebook and Workday, it also had its share of major mergers and… Continue reading 〉